Bayer's Asundexian Demonstrated a Substantial 26% Reduction in Stroke After a Non-Cardioembolic Ischemic Stroke or High-Risk Transient Ischemic Attack, With No Increase in ISTH Major Bleeding Versus Placebo
February 06, 2026
February 06, 2026
WHIPPANY, New Jersey, Feb. 6 -- Bayer USA, an enterprise with core competencies in the life science fields of health care and nutrition, issued the following news on Feb. 5, 2026:
* * *
Bayer's asundexian demonstrated a substantial 26% reduction in stroke after a non-cardioembolic ischemic stroke or high-risk transient ischemic attack, with no increase in ISTH major bleeding versus placebo
* In OCEANIC-STROKE, patients who received asundexian after a n . . .
* * *
Bayer's asundexian demonstrated a substantial 26% reduction in stroke after a non-cardioembolic ischemic stroke or high-risk transient ischemic attack, with no increase in ISTH major bleeding versus placebo
* In OCEANIC-STROKE, patients who received asundexian after a n . . .